- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IMAGENEBIO Aktie jetzt für 0€ handeln | |||||
| 10.10. | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | ImageneBio files to sell 2.51M shares of common stock for holders | 2 | Seeking Alpha | ||
| 08.09. | ImageneBio, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 05.08. | ImageneBio, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 01.08. | ImageneBio: Vorstand genehmigt Anreizplan 2025 zur Mitarbeitergewinnung | 2 | Investing.com Deutsch | ||
| 01.08. | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 127 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and... ► Artikel lesen | |
| 29.07. | ImageneBio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.07. | Ikena Oncology, Inc.: Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million | 249 | GlobeNewswire (Europe) | The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will... ► Artikel lesen | |
| 24.07. | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 23.07. | Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company | 1 | Investing.com | ||
| 23.07. | Ikena Oncology, Inmagene Biopharmaceuticals appoint Kristin Yarema, as CEO | 1 | Seeking Alpha | ||
| 23.07. | Ikena Oncology and Inmagene name Kristin Yarema as CEO of combined firm | 5 | Investing.com | ||
| 23.07. | Ikena Oncology, Inc.: Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company | 241 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema... ► Artikel lesen | |
| 22.07. | Ikena Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Ikena Oncology ändert Vergütungsvereinbarung für Dr. Jotin Marango vor Fusion | 1 | Investing.com Deutsch | ||
| 15.07. | Ikena Oncology, Inc.: Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals | 208 | GlobeNewswire (Europe) | Combined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc.... ► Artikel lesen | |
| 12.07. | ISS And Glass Lewis Support Ikena Oncology's Share Issuance For Proposed Inmagene Merger | 5 | RTTNews | ||
| 11.07. | Ikena Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.07. | Ikena Oncology, Inc.: Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote "FOR" Proposed Merger with Inmagene Biopharmaceuticals | 125 | GlobeNewswire (Europe) | BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," the "Company") today announced that Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co. ("Glass... ► Artikel lesen | |
| 01.07. | Ikena Oncology, Inc. - 8-K, Current Report | 3 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,822 | +1,91 % | Aixtron, Evotec, Hensoldt, Puma, Ströer, Suss MicroTec - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BIOGEN | 127,80 | +1,39 % | Patient Opportunity Equity strategy buys UNH, CROX, MAT, IAC, and BIIB | ||
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| MAINZ BIOMED | 1,540 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed to Attend 2025 Maxim Growth Summit | Issuer: Mainz BioMed N.V.
/ Key word(s): Conference
Mainz Biomed to Attend 2025 Maxim Growth Summit
15.10.2025 / 15:01 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,200 | -0,76 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity | Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735
Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,175 | -2,91 % | Cellectar Biosciences, Inc. - S-1, General form for registration of securities | ||
| GALAPAGOS NV | 27,020 | +0,52 % | Galapagos NV: Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation | Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos
Mechelen, Belgium;... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,874 | -2,29 % | Cardiff Oncology nach Daten-Dip: Jetzt kaufen? | Cardiff Oncology legt seine lang erwarteten Krebs-Daten vor und der Aktienkurs fährt Achterbahn: Bietet sich für Anleger ein neues Trading-Fenster, oder lässt man jetzt besser die Finger von dem Titel?... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,472 | -2,19 % | Coherus Oncology: Nach der Rallye folgt der Durchbruch? | Die Aktie von Coherus Oncology hat in den vergangenen Monaten deutlich an Dynamik gewonnen. Mit über 60 Prozent Kursplus seit April 2025 rückt das Unternehmen ins Rampenlicht - getragen von wachsenden... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 10,935 | 0,00 % | Sensei Biotherapeutics Shares Drop 34% On Phase 1/2 Trial Data Of Solnerstotug | ||
| CYTOKINETICS | 49,600 | -0,40 % | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | ||
| CYTOMX THERAPEUTICS | 3,166 | +1,60 % | CytomX Therapeutics Inc.: CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer | SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,100 | +2,94 % | GSK unveils positive pivotal data for Spero's once-rejected oral antibiotic | ||
| PERSONALIS | 8,285 | +0,36 % | Personalis, Inc.: Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing | Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate... ► Artikel lesen |
Das Unternehmen IMAGENEBIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 7,460 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMAGENEBIO INC finden Sie auf Wallstreet Online.